N-of-One today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed.
Guardant360 is the first pan-cancer blood test that helps oncologists prescribe the right treatments at the right time based on the changing genomics of a patient's cancer. The test uses trace fragments of tumor DNA that are shed into the bloodstream ("cell-free DNA") for reconstructing and sequencing a patient’s cancer to detect emergent alterations that can help oncologists better match patients to potential therapeutic options.
N-of-One’s clinical interpretation provides relevant biological and clinical knowledge related to the mutation profile of the identified tumor DNA, and links this state-of-the-art knowledge to relevant therapeutic strategies, including clinical trials, to support oncologists in making molecularly-informed, personalized treatment decisions.
"Guardant360 is the first comprehensive, non-invasive tumor sequencing test providing real-time answers," said Helmy Eltoukhy, Ph.D., Guardant Health's co-founder and chief executive officer. “Knowledge of genomic alterations in combination with potential therapies can be most helpful to an oncologist and the treatment of their patients."
“N-of-One provides diagnostic companies with best in class, state-of-the-art biological and clinical knowledge relevant to each test’s findings” said Chris Cournoyer, CEO of N-of-One. “Leveraging N-of-One clinical knowledge enables diagnostic companies to scale their test volumes in a cost effective manner.”